Contributing role of extracellular vesicles on vascular endothelium haemostatic balance in cancer

References

• Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007; 5: 632–4.
   PubMed Web of Science ®Google Scholar
• Falanga A, Russo L. Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hamostaseologie. 2012; 32: 115–25.
   PubMed Web of Science ®Google Scholar
• Gheldof D, Mullier F, Bailly N, Devalet B, Dogne JM, Chatelain B et al. Microparticle bearing tissue factor: a link between promyelocytic cells and hypercoagulable state. Thromb Res. 2014; 133: 433–9.
   Web of Science ®Google Scholar
• Lacroix R, Dignat-George F. Microparticles as a circulating source of procoagulant and fibrinolytic activities in the circulation. Thromb Res. 2012; 129(Suppl 2): S27–9.
   PubMed Web of Science ®Google Scholar
• Thomas GM, Panicot-Dubois L, Lacroix R, Dignat-George F, Lombardo D, Dubois C. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med. 2009; 206: 1913–27.
   PubMed Web of Science ®Google Scholar
• Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia. 2006; 20: 1487–95.
   PubMed Web of Science ®Google Scholar
• Anderson HC, Mulhall D, Garimella R. Role of extracellular membrane vesicles in the pathogenesis of various diseases, including cancer, renal diseases, atherosclerosis, and arthritis. Lab Invest. 2010; 90(11): 1549–57.
   Web of Science ®Google Scholar
• Gould SJ, Raposo G. As we wait: coping with an imperfect nomenclature for extracellular vesicles. J Extracell Vesicles. 2013; 2 20389, doi: http://dx.doi.org/10.3402/jev.v2i0.20389.
   PubMedGoogle Scholar
• Lefebvre H, Prevost G, Louiset E. Autocrine/paracrine regulatory mechanisms in adrenocortical neoplasms responsible for primary adrenal hypercorticism. Eur J Endocrinol. 2013; 169: R115–38.
   Web of Science ®Google Scholar
• Hesketh GG, Van Eyk JE, Tomaselli GF. Mechanisms of gap junction traffic in health and disease. J Cardiovasc Pharmacol. 2009; 54: 263–72.
   Web of Science ®Google Scholar
• Rustom A, Saffrich R, Markovic I, Walther P, Gerdes HH. Nanotubular highways for intercellular organelle transport. Science. 2004; 303: 1007–10.
   PubMed Web of Science ®Google Scholar
• Berckmans RJ, Sturk A, van Tienen LM, Schaap MC, Nieuwland R. Cell-derived vesicles exposing coagulant tissue factor in saliva. Blood. 2011; 117: 3172–80.
   PubMed Web of Science ®Google Scholar
• Lv LL, Cao Y, Liu D, Xu M, Liu H, Tang RN et al. Isolation and quantification of microRNAs from urinary exosomes/microvesicles for biomarker discovery. Int J Biol Sci. 2013; 9: 1021–31.
   PubMed Web of Science ®Google Scholar
• Huttner HB, Janich P, Kohrmann M, Jaszai J, Siebzehnrubl F, Blumcke I et al. The stem cell marker prominin-1/CD133 on membrane particles in human cerebrospinal fluid offers novel approaches for studying central nervous system disease. Stem Cells. 2008; 26: 698–705.
   PubMed Web of Science ®Google Scholar
• Lechner D, Kollars M, Gleiss A, Kyrle PA, Weltermann A. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J Thromb Haemost. 2007; 5: 2445–52.
   Web of Science ®Google Scholar
• Grange C, Tapparo M, Collino F, Vitillo L, Damasco C, Deregibus MC et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011; 71: 5346–56.
   PubMed Web of Science ®Google Scholar
• Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A. 2012; 109: E2110–16.
   PubMed Web of Science ®Google Scholar
• Jaiswal R, Gong J, Sambasivam S, Combes V, Mathys JM, Davey R et al. Microparticle-associated nucleic acids mediate trait dominance in cancer. Faseb J. 2012; 26: 420–9.
   PubMed Web of Science ®Google Scholar
• Castellana D, Kunzelmann C, Freyssinet JM. Pathophysiologic significance of procoagulant microvesicles in cancer disease and progression. Hamostaseologie. 2009; 29: 51–7.
   Web of Science ®Google Scholar
• Ghasemi R, Grassadonia A, Tinari N, Piccolo E, Natoli C, Tomao F et al. Tumor-derived microvesicles: the metastasomes. Med Hypotheses. 2013; 80: 75–82.
   PubMed Web of Science ®Google Scholar
• Lima LG, Monteiro RQ. Activation of blood coagulation in cancer: implications for tumour progression. Biosci Rep. 2013; 33: e00064.
   PubMed Web of Science ®Google Scholar
• Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol. 2009; 22: 49–60.
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Galea V, Mbemba E, Khaterchi A, Sassi M, Baccouche H et al. Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7. Thromb Res. 2012; 129: 779–86.
   Web of Science ®Google Scholar
• Mackman N. Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis. 2006; 36: 104–7.
   PubMed Web of Science ®Google Scholar
• Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumour cells and recognition by activated human blood monocytes. Cancer Res. 1991; 51: 3062–6.
   PubMed Web of Science ®Google Scholar
• Morrissey JH, Davis-Harrison RL, Tavoosi N, Ke K, Pureza V, Boettcher JM et al. Protein-phospholipid interactions in blood clotting. Thromb Res. 2010; 125(Suppl 1): S23–5.
   Web of Science ®Google Scholar
• Langer F, Ruf W. Synergies of phosphatidylserine and protein disulfide isomerase in tissue factor activation. Thromb Haemost. 2014; 111: 590–7.
   Web of Science ®Google Scholar
• Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost. 2004; 2: 2065–7.
   PubMed Web of Science ®Google Scholar
• Aharon A, Brenner B. Microparticles, thrombosis and cancer. Best Pract Res Clin Haematol. 2009; 22: 61–9.
   Web of Science ®Google Scholar
• Ameri A, Kuppuswamy MN, Basu S, Bajaj SP. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood. 1992; 79: 3219–26.
   Web of Science ®Google Scholar
• Connor DE, Exner T, Ma DD, Joseph JE. The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thromb Haemost. 2010; 103: 1044–52.
   PubMed Web of Science ®Google Scholar
• Arraud N, Linares R, Tan S, Gounou C, Pasquet JM, Mornet S et al. Extracellular vesicles from blood plasma: determination of their morphology, size, phenotype and concentration. J Thromb Haemost. 2014; 12(5): 614–27.
   PubMed Web of Science ®Google Scholar
• de Agostini AI, Watkins SC, Slayter HS, Youssoufian H, Rosenberg RD. Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. J Cell Biol. 1990; 111: 1293–304.
   PubMed Web of Science ®Google Scholar
• Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A. 1981; 78: 2249–52.
   PubMed Web of Science ®Google Scholar
• Esmon CT, Esmon NL. The link between vascular features and thrombosis. Annu Rev Physiol. 2011; 73: 503–14.
   PubMed Web of Science ®Google Scholar
• Blann AD. Endothelial cell activation markers in cancer. Thromb Res. 2012; 129(Suppl 1): S122–6.
   Web of Science ®Google Scholar
• Mesri M, Altieri DC. Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J Biol Chem. 1999; 274: 23111–18.
   PubMed Web of Science ®Google Scholar
• Aharon A, Tamari T, Brenner B. Monocyte-derived microparticles and exosomes induce procoagulant and apoptotic effects on endothelial cells. Thromb Haemost. 2008; 100: 878–85.
   PubMed Web of Science ®Google Scholar
• Yu J, May L, Milsom C, Anderson GM, Weitz JI, Luyendyk JP et al. Contribution of host-derived tissue factor to tumour neovascularization. Arterioscler Thromb Vasc Biol. 2008; 28: 1975–81.
   PubMed Web of Science ®Google Scholar
• Bode AM, Dong Z. The functional contrariety of JNK. Mol Carcinog. 2007; 46: 591–8.
   PubMed Web of Science ®Google Scholar
• Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, Schonbeck U. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem. 2002; 277: 25032–9.
   PubMed Web of Science ®Google Scholar
• Pan Y, Liang H, Liu H, Li D, Chen X, Li L et al. Platelet-secreted microRNA-223 promotes endothelial cell apoptosis induced by advanced glycation end products via targeting the insulin-like growth factor 1 receptor. J Immunol. 2014; 192: 437–46.
   PubMed Web of Science ®Google Scholar
• Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood. 1997; 89: 2429–42.
   PubMed Web of Science ®Google Scholar
• Pradier A, Ettelaie C. The influence of exogenous tissue factor on the regulators of proliferation and apoptosis in endothelial cells. J Vasc Res. 2008; 45: 19–32.
   Web of Science ®Google Scholar
• Varon D, Hayon Y, Dashevsky O, Shai E. Involvement of platelet derived microparticles in tumour metastasis and tissue regeneration. Thromb Res. 2012; 130(Suppl 1): S98–9.
   PubMed Web of Science ®Google Scholar
• Riedemann J, Macaulay VM. IGF1R signalling and its inhibition. Endocr Relat Cancer. 2006; 13(Suppl 1): S33–43.
   PubMed Web of Science ®Google Scholar
• Abid Hussein MN, Boing AN, Biro E, Hoek FJ, Vogel GM, Meuleman DG et al. Phospholipid composition of in vitro endothelial microparticles and their in vivo thrombogenic properties. Thromb Res. 2008; 121: 865–71.
   Web of Science ®Google Scholar
• Pasquier J, Thawadi HA, Ghiabi P, Abu-Kaoud N, Maleki M, Guerrouahen BS et al. Microparticles mediated cross-talk between tumoral and endothelial cells promote the constitution of a pro-metastatic vascular niche through Arf6 up regulation. Cancer Microenviron. 2014
   Google Scholar
• Terrisse AD, Puech N, Allart S, Gourdy P, Xuereb JM, Payrastre B et al. Internalization of microparticles by endothelial cells promotes platelet/endothelial cell interaction under flow. J Thromb Haemost. 2010; 8: 2810–19.
   PubMed Web of Science ®Google Scholar
• Andre P, Denis CV, Ware J, Saffaripour S, Hynes RO, Ruggeri ZM et al. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood. 2000; 96: 3322–8.
   PubMed Web of Science ®Google Scholar
• Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci U S A. 1995; 92: 7450–4.
   PubMed Web of Science ®Google Scholar
• Frenette PS, Denis CV, Weiss L, Jurk K, Subbarao S, Kehrel B et al. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet–endothelial interactions in vivo. J Exp Med. 2000; 191: 1413–22.
   PubMed Web of Science ®Google Scholar
• Brodsky SV, Zhang F, Nasjletti A, Goligorsky MS. Endothelium-derived microparticles impair endothelial function in vitro. Am J Physiol Heart Circ Physiol. 2004; 286: H1910–15.
   PubMed Web of Science ®Google Scholar
• Essayagh S, Xuereb JM, Terrisse AD, Tellier-Cirioni L, Pipy B, Sie P. Microparticles from apoptotic monocytes induce transient platelet recruitment and tissue factor expression by cultured human vascular endothelial cells via a redox-sensitive mechanism. Thromb Haemost. 2007; 98: 831–7.
   PubMed Web of Science ®Google Scholar
• Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res. 2004; 61: 498–511.
   PubMed Web of Science ®Google Scholar
• Jy W, Jimenez JJ, Mauro LM, Horstman LL, Cheng P, Ahn ER et al. Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation. J Thromb Haemost. 2005; 3: 1301–8.
   PubMed Web of Science ®Google Scholar
• Barry OP, Pratico D, Savani RC, FitzGerald GA. Modulation of monocyte–endothelial cell interactions by platelet microparticles. J Clin Invest. 1998; 102: 136–44.
   PubMed Web of Science ®Google Scholar
• Bombeli T, Schwartz BR, Harlan JM. Adhesion of activated platelets to endothelial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), alphavbeta3 integrin, and GPIbalpha. J Exp Med. 1998; 187: 329–39.
   PubMed Web of Science ®Google Scholar
• Elice F, Rodeghiero F. Hematologic malignancies and thrombosis. Thromb Res. 2012; 129: 360–6.
   PubMed Web of Science ®Google Scholar
• Wun T, White RH. Venous thromboembolism in patients with acute leukaemia, lymphoma, and multiple myeloma. Thromb Res. 2010; 125(Suppl 2): S96–102.
   PubMed Web of Science ®Google Scholar
• Hunault-Berger M, Chevallier P, Delain M, Bulabois CE, Bologna S, Bernard M et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukaemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica. 2008; 93: 1488–94.
   PubMed Web of Science ®Google Scholar
• Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005; 293: 715–22.
   PubMed Web of Science ®Google Scholar
• Ziegler S, Sperr WR, Knobl P, Lehr S, Weltermann A, Jager U et al. Symptomatic venous thromboembolism in acute leukaemia. Incidence, risk factors, and impact on prognosis. Thromb Res. 2005; 115: 59–64.
   PubMed Web of Science ®Google Scholar
• De Stefano V, Sora F, Rossi E, Chiusolo P, Laurenti L, Fianchi L et al. The risk of thrombosis in patients with acute leukaemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost. 2005; 3: 1985–92.
   PubMed Web of Science ®Google Scholar
• Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G, Franke A. Increased risk of venous thromboembolism in patients with acute leukaemia. Br J Cancer. 2006; 94: 200–2.
   PubMed Web of Science ®Google Scholar
• Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer. 2004; 101: 558–66.
   PubMed Web of Science ®Google Scholar
• Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol. 2001; 106(1–2): 6–12.
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2012; 2012: 571–81.
   Google Scholar
• Haim N, Lanir N, Hoffman R, Haim A, Tsalik M, Brenner B. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med. 2001; 110: 91–6.
   PubMed Web of Science ®Google Scholar
• Negaard HF, Iversen PO, Ostenstad B, Mowinckel MC, Sandset PM. Increased acquired activated protein C resistance in unselected patients with hematological malignancies. J Thromb Haemost. 2008; 6: 1482–7.
   Web of Science ®Google Scholar
• Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995; 85: 1504–8.
   PubMed Web of Science ®Google Scholar
• Thaler J, Pabinger I, Sperr WR, Ay C. Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. Thromb Res. 2014; 133: 303–5.
   Web of Science ®Google Scholar
• Auwerda JJ, Yuana Y, Osanto S, de Maat MP, Sonneveld P, Bertina RM et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost. 2011; 105: 14–20.
   PubMed Web of Science ®Google Scholar
• Duchemin J, Ugo V, Ianotto JC, Lecucq L, Mercier B, Abgrall JF. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res. 2010; 126: 238–42.
   PubMed Web of Science ®Google Scholar
• Blann AD, Gurney D, Wadley M, Bareford D, Stonelake P, Lip GY. Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagul Fibrinolysis. 2001; 12: 43–50.
   PubMed Web of Science ®Google Scholar
• Swystun LL, Shin LY, Beaudin S, Liaw PC. Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes. J Thromb Haemost. 2009; 7: 619–26.
   Web of Science ®Google Scholar
• Fu Y, Zhou J, Li H, Cao F, Su Y, Fan S et al. Daunorubicin induces procoagulant activity of cultured endothelial cells through phosphatidylserine exposure and microparticles release. Thromb Haemost. 2010; 104: 1235–41.
   Web of Science ®Google Scholar
• Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013; 31: 2189–204.
   PubMed Web of Science ®Google Scholar
• Zhang J, Defelice AF, Hanig JP, Colatsky T. Biomarkers of endothelial cell activation serve as potential surrogate markers for drug-induced vascular injury. Toxicol Pathol. 2010; 38: 856–71.
   PubMed Web of Science ®Google Scholar